(September 15, 2017, Guangzhou) Recently, the world's first large-scale tiotropium bromide treatment of early COPD clinical research led by the Guangzhou Institute of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University and the participation of many domestic hospitals (Tie-COPD) research results were published in the international top medical academic journal "New England Journal of Medicine". The results of the study show that inhalation of tiotropium bromide through a music suction device can effectively improve lung function, improve quality of life and reduce acute exacerbations in patients with early COPD, and it has been observed that the rate of decline in lung function has slowed.
Tie-COPD research results press conference
At the research results release press conference held today, the co-first author of the article, the academician of the Chinese Academy of Engineering, the director of the National Respiratory Diseases Clinical Medicine Research Center Professor Zhong Nanshan and the corresponding author of the article, Professor Ran Pixin, director of the Guangzhou Institute of Respiratory Diseases and the State Key Laboratory of Respiratory Diseases, jointly called for reshaping the concept of COPD diagnosis and treatment and attaching importance to early diagnosis and early treatment. The number of patients with chronic obstructive pulmonary disease is increasing. Early diagnosis cannot be ignored.
chronic obstructive pulmonary disease is currently one of the diseases with high morbidity and mortality in the world. In China, COPD has become one of the three deadliest health killers. The prevalence of chronic obstructive pulmonary disease among people over 40 years old in my country is 8.2%, that is, there are currently about 40 million COPD patients in my country.
The research team led by Academician Zhong Nanshan and Professor Ran Pixin found that more than 70% of COPD patients are early-stage patients (GOLD 1-2), and the symptoms of these patients are usually mild or no obvious breathing System symptoms, such as breathing difficulties, so most of the patients with early COPD did not actively seek medical help. They did not see a doctor until they had obvious symptoms such as shortness of breath and dyspnea. However, at this time, the lung function of the patients was often obviously affected. The best treatment time was missed.
Academician of the Chinese Academy of Engineering, Professor Zhong Nanshan, Director of the National Respiratory Diseases Clinical Research Center
The treatment effect of patients with advanced chronic obstructive pulmonary disease is poor, with high mortality, rehospitalization and disability rates, which has brought heavy burdens to patients’ families and society Burden. This is the reason why the treatment effect of COPD patients in the world is poor.
Moreover, the early lung function decline of COPD patients is more rapid. If effective methods can be found to intervene in early COPD patients, it will not only prevent the rapid decline of lung function in time, but also slow the progression of the disease. Reduce the huge pain and burden caused to patients, families and society in the late stage of the disease. Therefore, the team led by Academician Zhong Nanshan and Professor Ran Pixin of the Guangzhou Institute of Respiratory Diseases and the State Key Laboratory of Respiratory Diseases has been calling for early intervention studies of COPD to provide new strategies for improving the prevention and treatment of COPD.
Tie-COPD study results: Tiotropium is safe and effective in the treatment of early COPD patients
Tie-COPD ( The world's first large-scale tiotropium treatment of early COPD clinical study) is a randomized, double-blind, and comfort A drug-controlled multi-center study, led by the Guangzhou Institute of Respiratory Diseases and the participation of many domestic hospitals, explored the effectiveness and safety of tiotropium bromide in early COPD patients with no symptoms or only mild symptoms. The study started in October 2011 and ended in September 2015. A total of 841 GOLD level 1 and GOLD level 2 patients were enrolled. Professor Zhou Yumin of the Guangzhou Institute of Respiratory Diseases, one of the main investigators of the
Tie-COPD study, said that many patients in the study were selected through community screening because early COPD patients rarely go to the hospital for treatment. The study selected the current mainstream treatment of chronic obstructive pulmonary disease, a long-acting bronchodilator-tiotropium bromide, as the study drug, and a placebo as the control group. The primary endpoint of the study was the difference in FEV1 changes before bronchodilator between the two groups of patients after 2 years of treatment. The secondary endpoints included the difference in FEV1 changes between the two groups after bronchodilators, and the 1-year decline rate of FEV before and after bronchodilators. , Quality of life, acute exacerbation, etc.
Zhou, Doctor of the First Affiliated Hospital of Guangzhou Medical UniversityThe results of Professor Yumin's
study showed that compared with the placebo group, Tiotropium significantly improved the pre-bronchodilator FEV1 by 157ml (95% CI, 123-192, P<0.001)>
In terms of preventing acute exacerbations, the tiotropium bromide group took longer than the placebo group for the first acute exacerbation (P<0.001);>
(risk factor: 0.53, 95% CI, 0.39-0.73, P<0.001)>
has focused on COPD for more than 20 years, and the research results have been fruitful.
The COPD research team led by Academician Zhong Nanshan and Professor Ran Pixin achieved this research result is the result of many years of research. It is understood that the team has been focusing on the incidence and comprehensive prevention and treatment of COPD since the 1990s. They are supported by the national "Tenth Five-Year", "Twelfth Five-Year" and "13th Five-Year" scientific and technological projects. , Organized a number of units across the country to carry out joint research on the prevention and treatment of COPD, and achieved a series of research results.
Director of the State Key Laboratory of Respiratory Diseases, Professor Ran Pixin, Secretary of the Party Committee of Guangzhou Medical University. COPD community screening technology, established a COPD management system suitable for grassroots and community use and promotion, and formulated a hierarchical and precise comprehensive intervention model for the general population, high-risk COPD groups, and COPD patients. Groundbreaking research on suitable drugs for the treatment of chronic obstructive pulmonary disease suitable for national conditions.
Their series of research results were published in the top international journals such as The Lancet, Brit Med J, PLOS Med, etc., to formulate COPD prevention and treatment policies for my country And treatment guidelines provide an important scientific basis (the research results won the second prize of the 2015 National Science and Technology Progress Award); the results of this research have opened a new strategy for the diagnosis and treatment of COPD in the world. The clinical enlightenment of
Tie-COPD—— early diagnosis and treatment of COPD cannot be ignored. As a long-acting anticholinergic bronchodilator, tiotropium bromide has been recommended by domestic and foreign treatment guidelines as a stable CO Core therapeutic drugs have been widely used clinically.
Academician Zhong Nanshan pointed out that the results of the study are of great significance for the diagnosis and treatment of early COPD. It proves that in early COPD patients with no or mild symptoms, the use of a long-acting bronchodilator-tiotropium can be effective It brings significant clinical benefits to patients, which provides valuable insights for the treatment of early COPD: we need to reshape the concept of diagnosis and treatment of COPD, and achieve early diagnosis and treatment of COPD, just like Early treatment of hypertension and diabetes, so as to save the lung function of patients with COPD early and delay the progression of the disease.
